CARDIOVASCULAR JOURNAL OF AFRICA • Vol 24, No 3, April 2013
64
AFRICA
897–905.
5.
Scott-Burden T, Resink TJ, Hahn AW, Buhler FR. Angiotensin-induced
growth related metabolism is activated in cultured smooth muscle cells
from spontaneously hypertensive rats and Wistar-Kyoto rats.
Am J
Hypertens
1991;
4
: 183–188.
6.
Yayama K, Okamoto H. Angiotensin II-induced vasodilation via type
2 receptor: Role of bradykiniin and nitric oxide
. Int Immpharmacol
2008;
8
: 312–318.
7.
Ruilope LM, Lahera V, Rodicio JL, Carlos Romero J. Are renal hemo-
dynamics a key factor in the development and maintenance of arterial
hypertension in humans?
Hypertension
1994;
23
: 3–9.
8.
Ruilope LM, Alcazar JM, Hernandez E, Moreno F, Martinez MA,
Rodicio JL. Does an adequate control of blood pressure protect the
kidney in essential hypertension?
J Hypertens
1990;
8
: 525–531.
9.
Vogt M, Motz WH, Schwartzkopf B, Strauer BE. Pathophysiological
and clinical aspects of hypertensive hypertrophy.
Eur Heart J
1993;
14
(Suppl): 2–7.
10. DeDivitiss O, Clentano A, DeSimone G,
et al.
Management of patient
with left ventricular hypertrophy.
Eur Heart J
1993;
14
(Suppl): 22–32.
11. Shapiro LM, Sugden PH. Left ventricular Hypertrophy. In: Julian DG,
Camm AJ, Fox KM, Hall RTC, Poole-Wilson PA, eds.
Diseases of the
Heart
. 2nd edn. London; Saunders, 1996.
12. MacGregor GA. Blood pressure, angiotenin-converting enzyme (ACE)
inhibitors, and the kidney.
Am J Med
1992;
92
: 259–266.
13. Kang PM, Landan AJ, Eberhardt RT, Frishman WH. Irbesartan reduces
the albumin excretion rate.
Am Heart J
1994;
127
: 1388–1401.
14. Goldberg MR, Bradstreet TE, McWilliams EJ,
et al
. Biochemical
effects of losartan, a nonpeptide angiotenisn II receptor antagonist,
on the renin-angiotensin-aldosterone system in hypertensive patients.
Hypertension
1995;
25
: 37–46.
15. Berecek KH, Zhang L. In: Mukhopdhyay AK, Raizada MK, eds.
Tissue
Renin Angiotenisn Systems.
NewYork: Plenum, 1995: 141–168.
16. Swynghedauw R, Delcayre C. Biology of cardiac over-load.
Pathabiol
Annu
1982;
12
: 137–183.
17. Doggrell SA, Brown L. Rat models of hypertension, cardiac hypertro-
phy and failure.
Cardiovasc Res
1998;
39
: 89–105.
18. Yayama K, Horii M, Hiyoshi H,
et al
. Up-regulation of angiotensin II
type 2 receptor rat thoracic aorta by pressure-overlaod.
J Pharmacol
Exp Therapeut
2004;
308
: 736–743.
19. Clariborne L.
Handbook of Methods for Oxygen Radical Research
.
London: CRC Press, 1985.
20. Misra HP, Frodovich I. The role of superoxide anion in the autoxidation
of epinephrine and a simple assay for superoxide dismutase.
J Biol
Chem
1972;
247
: 3170–3175.
21. Brady N, Merval R, Benessiano J, Samuel JL, Tedgui A. Pressure and
angiotensin II synergistically induce aortic fibronectin expression in
organ culture model of rabbit aorta. Evidence for a pressure-induced
tissue renin-angiotensin system.
Cir Res
1996;
79
: 70–78.
22. Bonnet F, Cooper ME, Carey RM, Casley D, Cao Z. Vascular expres-
sion of angiotensin type 2 receptor in the adult rat: influence of angio-
tensin II infusion.
J Hypertens
2001;
19
: 1075–1081.
23. Baker KM, Chernin MI, Wixson SK, Aceto JF. Renin-angiotensin
system involvement in pressure-overload cardiac hypertrophy in rats.
Am J Physiol
1990;
259
: H324–H332.
24. Nouet S, Nahmias C. Signal transduction from the angiotensin II AT2
receptor.
Trends Endocrinol Metab
2000;
11
: 1–6.
25. Goa KL, Wagstaff AJ. Losartan potassium: a review of its pharmacol-
ogy, clinical efficacy and tolerability in the management of hyperten-
sion.
Drugs
1996;
51
: 820–845.
26. Chiolero A, Burnier M. Pharmacology of valsartan, an angiotensin II
receptor antagonist.
Expert Opin Investig Drug
1998;
7
: 1915–1925.
27. Gillis JC, Markham A. Irbesartan: a review of its pharmacodynamic
and pharmacokinetic properties and therapeutic use in the management
of hypertension.
Drugs
1997;
54
: 885–902.
28. Sever P. Candesartan cilexetil: a new, long-acting, effective angiotensin
II type 1 receptor blocker.
J Hum Hypertens
1997;
11
(Suppl 2): S91–95.
29. McClellan KJ, Markham A. Telmisartan.
Drugs
1998;
56
: 1039–1044.
30. McClellan KJ, Balfour JA. Eprosartan.
Drugs
1998;
55
: 713–718.
31. Spinale FG, DeGasparo M, Whitehead S,
et al
. Modulation of the renin-
angiotensin pathway through enzyme inhibition and specific receptor
blockade in pacing-induced heart failure I: effects on left ventricular
performance and neurohormonal systems.
Circulation
1997;
96
:
2385–2396.
32. Hayashi N, Fujimura Y, Yamamoto S,
et al.
Pharmacological profile
of valsartan, a non-peptide angiotensin II type 1 receptor profile. 4th
communication: Improvement of heart failure of rats with myocardial
infarction by valsartan.
Arzneim-Forsch/Drugs Res
1997;
47
: 625–629.
33. Mizuno K, Niimura S, Katoh K, Fukuchi S. TCV-116, a newly devel-
oped angiotensin II receptor antagonist, induces regression of cardiac
hypertrophy through suppression of the tissue reninangiotensin system
in spontaneously hypertensive rats.
Life Sci
1994;
54
: 1987–1994.
34. MacKenzie H, Ots M, Ziai F, Lee KW, Kato S, Brenner BM.
Angiotensin receptor antagonists in experimental models of chronic
renal failure.
Kidney Int
1997;
63
(Suppl): S140–143.
35. Remuzzi A, Fassi A, Sangalli F, Malanchini B, Mohamed EI, Bertani T,
Remuzzi G. Prevention of renal injury in diabetic MWF rats by angio-
tensin II antagonism.
Exp Nephrol
1998;
6
:
28–38.
36. Gradman AH, Arcuri KE, Goldberg AI,
et al
. A randomized, placebo-
controlled, double-blind, parallel study of various doses of losartan
potassium compared with enalapril maleate in patients with essential
hypertension.
Hypertension
1995;
25
: 1345–1350.
37. Black HR, Graff A, Shute D,
et al
. Valsartan, a new angiotensin II
antagonist for the treatment of essential hypertension: efficacy, toler-
ability and safety compared to an angiotensin-converting enzyme
inhibitor, lisinopril
. J Human Hypertens
1997;
11
: 483–489.
38. Mimran A, Ruilope L, Kerwin L,
et al
. A randomised, double-blind
comparison of the angiotensin II receptor antagonist, irbesartan, with
the full dose range of enalapril for the treatment of mild-tomoderate
hypertension
. J Human Hypertens
1998;
12
: 203–208.
39. Zanchetti A, Omboni S, DiBaggio C, on behalf of the study group.
Candesartan, cilexetil and enalapril are of equivalent efficacy in
patients with mild to moderate hypertension.
J Human Hypertens
1997;
11
(Suppl 2): S57–59.
40. Smith DHG, Neutel JM, Morgenstern P. Once-daily telmisartan
compared with enalapril in the treatment of hypertension.
Adv Ther
1998;
15
: 229–240.
41. Sawyer DB, Siwik DA, Xiao L, Pimentel DR, Singh K, Colucci WS.
Role of oxidative stress in myocardial hypertrophy and failure.
J Mol
Cell Cardiol
2002;
34
: 379–388.
42. Banerjee SK, Sood S, Dinda AK, Das TK, Maulik SK. Chronic oral
administration of raw garlic protects against isoproterenol-induced
myocardial necrosis in rat.
Comp Biochem Physiol
2003;
C136
:
377–386.
43. Panda VS, Naik SR. Cardioprotective activity of
Ginkgo biloba
phytosomes in isoproterenol-induced myocardial necrosis in rats: a
biochemical and histoarchitectural evaluation.
Exp Toxicol Pathol
2008;
60
: 397–404.
44. Takaya T, Kawashima S, Shinohara M, Yamashita T, Toh R, Sasaki N,
et al
. Angiotensin II type 1 receptor blocker telmisartan suppresses
superoxide production and reduces atherosclerotic lesion formation in
apolipoprotein E-deficient mice.
Atherosclerosis
2006;
186
: 402–410.
45. Khafer N, Singal PK. Modulatin of oxidative stress by a selective inhi-
bition of angiotensin II type 1 receptors in MI rats
. J Am Coll Cardiol
2001;
37
: 1461–1466.
46. Frimm CC, Sun Y, Weber KT. Angiotensin II receptor blockade and
myocardial fibrosis of the infarcted rat heart.
J Lab Clin Med
1997;
129
: 439–446.
47. Scheiffer B, Wirgh A, Meylerunn M. Comparative effects of chronic
angiotensin converting enzyme inhibition and angiotensin II type 1
receptor blockade on cardiac remodelling after myocardial infarction in
the rat.
Circulation
1994;
88
: 2273–2282.
48. Gupta M, Singal PK. Higher antioxidative capacity during a chronic
stable heart hypertrophy.
Circ Res
1989;
64
: 398–406.
49. Kanter MM, Hamlin RL, Unverferth DV, Davis HW, Merola AJ. Effect
of exercise training on antioxidant enzymes and cardiotoxicity of doxo-
rubicin.
J Appl Physiol
1985;
59
: 1298–1303.
50. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy.
N Engl
J Med
1998;
339
: 900–905.
